Tenaya Therapeutics Inc (TNYA) - Total Liabilities
Based on the latest financial reports, Tenaya Therapeutics Inc (TNYA) has total liabilities worth $22.11 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Tenaya Therapeutics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Tenaya Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Tenaya Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Tenaya Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Journey Medical Corp
NASDAQ:DERM
|
USA | $62.74 Million |
|
NH SPAC 2
KQ:206640
|
Korea | ₩37.46 Billion |
|
Diamond Building Products Public Company Limited
BK:DRT
|
Thailand | ฿1.67 Billion |
|
Atrem S.A.
WAR:ATR
|
Poland | zł152.29 Million |
|
SR Bancorp, Inc. Common stock
NASDAQ:SRBK
|
USA | $959.00 Million |
|
CBO Territoria S.A.
PA:CBOT
|
France | €227.60 Million |
|
Hannong Chem
KO:011500
|
Korea | ₩67.11 Billion |
|
Lyko Group A
ST:LYKO-A
|
Sweden | Skr2.07 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Tenaya Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Tenaya Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tenaya Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tenaya Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Tenaya Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $27.09 Million | -12.88% |
| 2023-12-31 | $31.09 Million | -12.59% |
| 2022-12-31 | $35.57 Million | -6.69% |
| 2021-12-31 | $38.12 Million | +337.07% |
| 2020-12-31 | $8.72 Million | -89.33% |
| 2019-12-31 | $81.74 Million | -- |
About Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ve… Read more